Cooley advised Cell Design Labs on its sale to Gilead Sciences. The transaction is valued at up to $567 million and includes Gilead’s acquisition of all outstanding shares of Cell Design Labs, including the shares of Cell Design Labs held by Kite Pharma (a subsidiary of Gilead). Partners Ben Beerle and Jamie Leigh led a broad Cooley team advising Cell Design Labs.
Palo Alto, Calif. – Cooley advised Versartis on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the Nasdaq Global Stock Market under the symbol "VSAR."
Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.
Cooley advised Principia Biopharma on its $122.2 million initial public offering of 7,187,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Lawyers David Peinsipp, Drew Williamson, Barbara Kosacz and Amanda Busch led the Cooley team advising the company.
Bank of America Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Robert W. Baird acted as lead manager.
Principia Biopharma, which now trades on the Nasdaq Global Select Market as “PRNB,” is a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.
DBV Technologies Completes Concurrent Public Offerings
November 6, 2014
Cooley advised the underwriters on DBV Technologies' concurrent $106.4 million initial public offering and $28.3 million secondary public offering on Euronext.
DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company trades on the Nasdaq Global Market under the symbol "DBVT" and on Euronext under the symbol "DBV."
Citigroup Global Markets, Leerink Partners and Bryan, Garnier & Co. acted as joint global coordinators and joint book running managers of the global offering.
Cooley advised Aduro Biotech on its $137 million initial public offering. Aduro is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company trades on the Nasdaq Global Market under the symbol "ADRO." Aduro also raised an additional $25 million in a private placement with Novartis Institutes for BioMedical Research, which closed concurrently with the offering.